Novavax clearing the way for a potential emergency approval_老虎社区_美港股上老虎

Novavax clearing the way for a potential emergency approval

RudolfKennedy
2022-01-01

$Novavax(NVAX)$ This was how it was report on Hill. This is how it should've been. Not baseless assumption added articles by Politico and Reuters.

"Novavax filed final data with the Food and Drug Administration (FDA) for its COVID-19 vaccine, clearing the way for a potential emergency approval next year.

The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson & Johnson.

If all goes well, Novavax could seek emergency approval next month as the U.S. continues to prioritize booster shots amid a spike in confirmed coronavirus cases driven by the highly transmissible omicron variant".

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":692509310,"tweetId":"692509310","gmtCreate":1641016850534,"gmtModify":1641019574272,"author":{"id":9000000000000404,"idStr":"9000000000000404","authorId":9000000000000404,"authorIdStr":"9000000000000404","name":"RudolfKennedy","avatar":"https://static.tigerbbs.com/4bf2f8692df593c0e58239fd56abf27c","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Novavax clearing the way for a potential emergency approval","extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a> This was how it was report on Hill. This is how it should've been. Not baseless assumption added articles by Politico and Reuters. \"Novavax filed final data with the Food and Drug Administration (FDA) for its COVID-19 vaccine, clearing the way for a potential emergency approval next year. The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson &amp; Johnson. If all goes well, Novavax could seek emergency approval next month as the U.S. continues to prioritize booster shots amid a spike in confirmed coronavirus cases driven by the highly transmissible omicron variant\". </body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a> This was how it was report on Hill. This is how it should've been. Not baseless assumption added articles by Politico and Reuters. \"Novavax filed final data with the Food and Drug Administration (FDA) for its COVID-19 vaccine, clearing the way for a potential emergency approval next year. The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson &amp; Johnson. If all goes well, Novavax could seek emergency approval next month as the U.S. continues to prioritize booster shots amid a spike in confirmed coronavirus cases driven by the highly transmissible omicron variant\". </body></html>","text":"$Novavax(NVAX)$ This was how it was report on Hill. This is how it should've been. Not baseless assumption added articles by Politico and Reuters. \"Novavax filed final data with the Food and Drug Administration (FDA) for its COVID-19 vaccine, clearing the way for a potential emergency approval next year. The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson & Johnson. If all goes well, Novavax could seek emergency approval next month as the U.S. continues to prioritize booster shots amid a spike in confirmed coronavirus cases driven by the highly transmissible omicron variant\".","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/692509310","repostId":0,"isVote":1,"tweetType":1,"viewCount":1617,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVAX"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":643,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Novavax clearing the way for a potential emergency approval

评论（1）

热议股票